Publications by authors named "Katya Rubinstein"

Claim this Profile
M
Mobile Therapeutic Attention for Treatment-Resistant Schizophrenia (m-RESIST) Solution for Improving Clinical and Functional Outcomes in Treatment-Resistant Schizophrenia: Prospective, Multicenter Efficacy Study.
Jussi Seppälä, Eva Grasa, Anna Alonso-Solis, Alexandra Roldan-Bejarano, Marianne Haapea, Katya Rubinstein

JMIR Hum Factors· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
m-RESIST, a Mobile Therapeutic Intervention for Treatment-Resistant Schizophrenia: Feasibility, Acceptability, and Usability Study.
Eva Grasa, Jussi Seppälä, Anna Alonso-Solis, Marianne Haapea, Matti Isohanni, Katya Rubinstein

JMIR Form Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Method to Compare the Delivery of Psychiatric Care for People with Treatment-Resistant Schizophrenia.
Anna Alonso-Solís, Susana Ochoa, Eva Grasa, Katya Rubinstein, Asaf Caspi

Int J Environ Res Public Health· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review.
Jussi Seppälä, Ilaria De Vita, Timo Jämsä, Jouko Miettunen, Matti Isohanni, Katya Rubinstein

JMIR Ment Health· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers.
Anna Alonso-Solís, Katya Rubinstein, Iluminada Corripio, Erika Jaaskelainen, Annika Seppälä

BMJ Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study.
Revital Amiaz, Ilan Kent, Katya Rubinstein, Ben Ami Sela, Daniel Javitt

Isr J Psychiatry Relat Sci· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study.
Elena Huerta-Ramos, Maria Soledad Escobar-Villegas, Katya Rubinstein, Zsolt Szabolcs Unoka, Eva Grasa

JMIR Mhealth Uhealth· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.
Mark Weiser, Ari A Gershon, Katya Rubinstein, Camelia Petcu, Maria Ladea

Schizophr Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis